

Inhibiting novel mechanisms of thrombosis

Thomas, Mark R.; Nicolson, Phillip

DOI:

[10.1080/09537104.2020.1853422](https://doi.org/10.1080/09537104.2020.1853422)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Thomas, MR & Nicolson, P 2021, 'Inhibiting novel mechanisms of thrombosis: next-generation antiplatelet therapy', *Platelets*, vol. 32, no. 1, pp. 5-6. <https://doi.org/10.1080/09537104.2020.1853422>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

This is an Accepted Manuscript version of the following article, accepted for publication in *Platelets*. Mark R. Thomas & Phillip L. R. Nicolson (2021) Inhibiting novel mechanisms of thrombosis: next-generation antiplatelet therapy, *Platelets*, 32:1, 5-6, DOI: 10.1080/09537104.2020.1853422. It is deposited under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Inhibiting novel mechanisms of thrombosis: next-generation antiplatelet therapy

Aspirin, which was first marketed in the 19th century, demonstrated an impressive mortality benefit in patients with myocardial infarction (MI) in the ISIS-2 trial in 1988.¹ Ever since, aspirin has formed the backbone of treatment for arterial thrombosis. Later, the platelet P2Y₁₂ inhibitor clopidogrel also proved to be an effective treatment for arterial thrombosis, particularly in the context of coronary artery disease, stroke and peripheral arterial disease. Patients with acute coronary syndromes (ACS) benefit from 1 year of treatment with a P2Y₁₂ inhibitor in combination with aspirin. In this setting, the potent P2Y₁₂ inhibitors ticagrelor and prasugrel have now largely replaced clopidogrel, due to a more effective reduction in atherothrombotic events.² However, this comes at the expense of an increase in bleeding, which particularly limits the long-term use of P2Y₁₂ inhibitors.

So, where do we go from here? William Parker and Robert Storey argue that we have scope to improve on our current use of aspirin and P2Y₁₂ inhibitors.³ They discuss that some patients may benefit from extended duration of P2Y₁₂ inhibition, as recent studies have shown benefit of long-term use of aspirin and ticagrelor in patients with diabetes and previous percutaneous coronary intervention, for example. They also highlight the novel potent P2Y₁₂ inhibitor selatogrel, which is administered subcutaneously and provides a rapid onset of action, thereby opening up all new possibilities for P2Y₁₂ inhibition. Whilst for other patients, less is more. Patients with ACS at high risk of bleeding may benefit from early discontinuation of aspirin and continuation of ticagrelor alone as this causes less bleeding. Alternatively, perhaps a lower dose of aspirin in combination with a P2Y₁₂ inhibitor could be the answer in the future?

The broad, potent antiplatelet effects of aspirin and P2Y₁₂ inhibitors inevitably interfere with haemostasis and can cause major bleeding, which has a similar impact on overall mortality as recurrent MI.⁴ Therefore, the development of novel antiplatelet agents with potent antithrombotic effects, but less impact on haemostasis, offers an appealing approach to reducing overall mortality. To this end, Fawaz Alenazy describes several promising novel antiplatelet drugs (including inhibitors of platelet GPVI, PAR4 and P-selectin, amongst others) that are currently under investigation in early-phase clinical trials. In total, this review comprehensively summarises 11 antiplatelet agents currently undergoing clinical studies as well as many more not far behind at the animal model or in-vitro stage.

Maan Harbi and colleagues specifically focus on the platelet receptors GPVI and CLEC-2 as novel antiplatelet targets.⁵ These particular pathways have critical roles in arterial thrombosis and inflammation-driven thrombosis respectively, with only minimal roles in haemostasis. These pathways have proven elusive to conventional small molecule inhibitors and antibody-based approaches are currently under evaluation in clinical trials. Downstream signalling of GPVI and CLEC-2 is mediated by Btk and SYK, which are also targeted by drugs that are currently used in the treatment of haematological malignancy and idiopathic thrombocytopenia. Repurposing these drugs as antithrombotic drugs therefore also offers another intriguing treatment strategy. The benefits of GPVI and CLEC-2 inhibitors could also extend beyond arterial thrombosis, with possible benefits in venous thrombo-embolism, sepsis and other inflammation-driven thrombosis.

Nithya Prasannan and Marie Scully describe the critical role of VWF and GPI in thrombosis and haemostasis.⁶ In particular, they highlight the transformational impact of caplacizumab, which blocks the interaction between VWF and GPIb, in the treatment of the devastating condition thrombotic thrombocytopenic purpura. They explore whether inhibition of the VWF-GPIb axis may also be beneficial in other types of thrombosis, although the critical role of this pathway in haemostasis is likely to be a limiting factor.

These review articles demonstrates just how far antiplatelet therapy has advanced in the last few decades and highlights the many exciting new possibilities still ahead of us.

References

1. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. *Lancet* 1988; 2: 349–360.
2. Collet J-P, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. Epub ahead of print 2020. DOI: 10.1093/eurheartj/ehaa575.
3. Parker WAE, Storey RF. Novel approaches to P2Y12 inhibition and aspirin dosing. *Platelets* 2020; 1–8.
4. Marquis-Gravel G, Dalgaard F, Jones AD, et al. Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. *J Am Coll Cardiol* 2020; 76: 162–171.
5. Harbi MH, Smith CW, Nicolson PLR, et al. Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases. *Platelets*.
6. Prasannan N, Scully M. Novel antiplatelet strategies targeting VWF and GPIb. *Platelets* 2020; 1–5.